1 / 40

Phase II Study of Temozolomide and Thalidomide in

Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors J Clin Oncol . 2006 Jan 20;24(3):401-6. Vs 劉俊煌 CR 周益聖. 財團法人台灣癌症臨床研究發展基金會. Outline. Classification and grading of NET Introduction to temozolomide Inclusion and exclusion criteria

kirsi
Télécharger la présentation

Phase II Study of Temozolomide and Thalidomide in

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic NeuroendocrineTumors J ClinOncol. 2006 Jan 20;24(3):401-6. Vs 劉俊煌 CR 周益聖 財團法人台灣癌症臨床研究發展基金會

  2. Outline • Classification and grading of NET • Introduction to temozolomide • Inclusion and exclusion criteria • Regimen dosage and adjustment • Response assessment • Result • Disscusion • Conclusion

  3. Endocr Relat Cancer. 2004 Mar;11(1):1-18.

  4. Endocr Relat Cancer. 2004 Mar;11(1):1-18.

  5. Outline • Classification and grading of NET • Introduction to temozolomide • Inclusion and exclusion criteria • Regimen dosage and adjustment • Response assessment • Result • Disscusion • Conclusion

  6. Cancer Chemother Pharmacol (2009) 64:647–655

  7. Cancer Chemother Pharmacol (2009) 64:647–655

  8. J Clin Oncol 25:4127-4136

  9. Temozolomide dosing regimens for malignant gliomas J Clin Oncol 25:4127-4136

  10. The Oncologist 2007;12:1114–1123

  11. The Oncologist 2007;12:1114–1123

  12. Outline • Classification and grading of NET • Introduction to temozolomide • Inclusion and exclusion criteria • Regimen dosage and adjustment • Response assessment • Result • Disscusion • Conclusion

  13. Inclusion (1)‏ • Histologically confirmed, locally unresectable or metastatic neuroendocrine tumors • Prior treatment with chemotherapy, other than DTIC, temozolomide, or thalidomide, was permitted • ECOG performance status of 0, 1, or 2 • Life expectancy > 12 weeks • Adequate renal function (serum creatinine < 1.5 * the upper limit of normal [ULN])‏

  14. Inclusion (2)‏ • Adequate hepatic function (total and direct bilirubin < 2 * the ULN)‏ • ALT and AST < 5 * the ULN, and alkaline phosphatase < 2 * the ULN or < 5 * the ULN in the setting of liver metastases • Adequate bone marrow function (absolute neutrophil count >1,500/mm3, platelets > 100,000/mm3, hemoglobin >9 g/dL)‏

  15. Exclusion • Clinically apparent CNS metastases or carcinomatous meningitis • History of myocardial infarction 6 months before protocol treatment • History of major surgery within 2 weeks before treatment initiation • HIV infection or AIDS-related illness • Other serious medical or psychiatric illness • Insufficient recovery from toxicities of prior therapies • Pregnant or lactating.

  16. Outline • Classification and grading of NET • Introduction to temozolomide • Inclusion and exclusion criteria • Regimen dosage and adjustment • Response assessment • Result • Disscusion • Conclusion

  17. Treatment Program • Temozolomide • 150 mg/m2 days 1 to 7 and days 15 to 21 • Thalidomide • daily • starting dose of 200 mg • Every 28 days

  18. Temozolomide adjustment • Hold if • ANC less than 1,000/mm3 • Plt less than 50,000/mm3 • all nonhematologic toxicities with National Cancer Institute Common Toxicity Criteria grade 2 or higher • Not resumed until full hematologic recovery • On recovery, dose reduction of 50 mg/m2 • Discontineud if • Unable to resume therapy within 3 weeks • Unacceptable toxicity levels

  19. Thalidomide adjustment • Increased weekly by 100 mg until a maximum dose of 400 mg • Before escalation • Toxicity >> reduced by 100 mg/d • No improvement within 7days >> further reduced by 50 mg • Not tolerate 50 mg/d >> removed from study • After escalation • Toxicity >> decreased by 100 mg • not resolved to grade 1 within 7 days >> further reduced by 100 mg • P't at a dose of 100 mg >> reduction to 50 mg daily

  20. Outline • Classification and grading of NET • Introduction to temozolomide • Inclusion and exclusion criteria • Regimen dosage and adjustment • Response assessment • Result • Disscusion • Conclusion

  21. Response assessment • Every 8 weeks after initiation of treatment • Computed tomography scan • P't with complete [CR] or partial response [PR] or stable disease remained on treatment until progression • CR • disappearance of all target lesions • at least 4 weeks

  22. Response assessment • PR • decrease of more than 30% in the sum of the largest perpendicular diameters of all measurable lesions • at least 4 weeks • without progression of any nonmeasurable sites • Without new lesions. • Progressive disease • increase of 20% or more in the sum of longest diameters of target lesions • one or more new lesions

  23. Response assessment • Stable disease: • Neither PR, nor progressive disease • Biochemical response • secondary end point • PR:decrease in chromogranin A by 50% or more • Stable: <50 % decrease or <25% increase

  24. Outline • Classification and grading of NET • Introduction to temozolomide • Inclusion and exclusion criteria • Regimen dosage and adjustment • Response assessment • Result • Disscusion • Conclusion

  25. Duration of Treatment • 29 patients received treatment for a median of 7.3 months (range, 1 to 23 months)‏ • 1 patient required dose reduction of temozolomide due to thrombocytopenia • 16patients required dose reductions for thalidomide-related toxicities • 14 required dose reduction to 100 mg • 2 required dose reductions to 50 mg daily • 9 patients continued thalidomide at their starting dose of 200 mg • 4 patients able to undergo dose escalation to 400 mg • Median thalidomide dose 100 mg/d

  26. Treatment-related toxicities resulting in discontinuation: neuropathy (11 patients,38%, 6 pt's persist > 3 wks), infection (four patients), thrombocytopenia (four patients), neutropenia (one patient), rash (one patient). Infections included: Pneumocystis carinii pneumonia (one patient), disseminated varicella zoster virus (one patient), staphylococcal sepsis (one patient), cutaneous herpes zoster (one patient)‏

  27. Median time to treatment discontinuation for toxicity :8.4 months (range, 1.5 to 7.5 months)‏

  28. Median duration of response was 13.5 months (range, 2 to 31 months)‏

  29. Progression-free survival Overall survival 1-year survival rate: 79% 2-year survival rate: 61%

  30. Outline • Classification and grading of NET • Introduction to temozolomide • Inclusion and exclusion criteria • Regimen dosage and adjustment • Response assessment • Result • Disscusion • Conclusion

  31. Discussion • Overall objective radiologic response rate of 25%(CR+PR)‏ • Biochemical response rate of 40% • 2-year survival rate of 61% • Unique toxicities:neuropathy(38%) and selective lymphopenia(69%)‏

  32. Carcinoid tumor • Objective response rates of streptozocin-based regimens: 16% to 33% • J Clin Oncol 2:1255-1259, 1984 • Cancer Clin Trials2:327-334, 1979 • J Clin Oncol 23:4897-4904, 2005 • Pancreatic endocrine tumors • Combined biochemical and radiologic response rate of . Streptozocin and doxorubicin : 69% • N Engl J Med 326:519-523, 1992 • Overall response rate of retrospective study of streptozocin, fluorouracil, and doxorubicin:39% • J Clin Oncol 22:4762-4771, 2004 • Cancer 86:944-948, 1999 • Am JClin Oncol 27:485-488, 2004

  33. CR+PR • Carcinoid tumor • 1/15 (7%)‏ • Pancreatic endocrine tumors • 5/11(45%) • Pheochromocytoma • 1/3 (33%)‏

  34. high proportion (55%) removed for toxicity • Median time to treatment discontinuation for treatment-related toxicity:8.4 months • 4 patients experienced progressive disease while receiving study therapy • Prophylaxis against P carinii pneumonia and herpes simplex virus should be utilized

  35. Outline • Classification and grading of NET • Introduction to temozolomide • Inclusion and exclusion criteria • Regimen dosage and adjustment • Response assessment • Result • Disscusion • Conclusion

  36. Conclusion • Combination of temozolomide and thalidomide seems to be an active oral regimen for the treatment of metastatic neuroendocrine tumors and alternative to intravenous regimens • More active in pancreatic endocrine tumors than in carcinoid tumors. • Further studies to more precisely assess the relative efficacy of this regimen in pancreatic endocrine and carcinoid tumors • Also to assess the relative contributions of temozolomide and thalidomide to the antitumoractivity

More Related